Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00342056 · ClinicalTrials.gov registry record
Role of Gene Variation in Effectiveness of Gleevec Treatment
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 100
- Enrollment target
NCT00342056: Completed study, sponsored by National Cancer Institute (NCI).
NCT00342056 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00342056 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
This study will examine DNA from cancer patients previously treated with Gleevec to look for a variation (mutation) of the ABCG2 gene that may render the drug less effective in certain patients. Gleevec is used to treat chronic myeloid leukemia and gastrointestinal tumors. Although most patients respond to treatment, many with advanced disease develop resistance to the drug. It is thought that in some patients this resistance results from the action of a protein that causes Gleevec to be pumped out of the cells, reducing its usefulness. Patients enrolled in clinical trials of Gleevec at the National Cancer Institute and at other participating institutions are eligible for this study. DNA from patients' blood samples are analyzed for the ABCG2 gene and correlated with clinical data, such as the patient's age, race, disease state, weight, height, and body surface area. It will also look at the drug dose, how often the drug is given, the duration of treatment, side effects and other medications taken.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00342056
The ClinicalTrials.gov registry entry for NCT00342056 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00342056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00342056 about?
NCT00342056 is a clinical study titled "Role of Gene Variation in Effectiveness of Gleevec Treatment". This study will examine DNA from cancer patients previously treated with Gleevec to look for a variation (mutation) of the ABCG2 gene that may render the drug less effective in certain patients. Gleevec is used to treat chronic myeloid leukemia and gastrointestinal tumors. Although most patients res...
What is the current status of trial NCT00342056?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2005-01. Estimated completion is 2008-10.
Who is sponsoring clinical trial NCT00342056?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.